Stock Track | Vir Biotechnology Soars 56.12% on Major Astellas Collaboration, Positive Clinical Data and Strong Earnings

Stock Track

Feb 24

Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.

The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its experimental prostate cancer treatment. Under the deal, Vir will receive $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and is eligible for up to an additional $1.37 billion in milestone payments plus royalties on ex-U.S. sales.

Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1132411650"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132411650\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132411650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132411650","market":"hk","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Soars 56.12% on Major Astellas Collaboration, Positive Clinical Data and Strong Earnings","media":"Stock Track","content":"<p>Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.</p><p>The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its experimental prostate cancer treatment. Under the deal, Vir will receive $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and is eligible for up to an additional $1.37 billion in milestone payments plus royalties on ex-U.S. sales.</p><p>Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Soars 56.12% on Major Astellas Collaboration, Positive Clinical Data and Strong Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Soars 56.12% on Major Astellas Collaboration, Positive Clinical Data and Strong Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.</p><p>The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its experimental prostate cancer treatment. Under the deal, Vir will receive $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and is eligible for up to an additional $1.37 billion in milestone payments plus royalties on ex-U.S. sales.</p><p>Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1132411650","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132411650","pubTimestamp":1771894940,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.The biopharmaceutical firm entered into a global...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|Vir Biotechnology飙升56.12%，得益于安斯泰来重大合作、积极的临床数据和强劲的盈利","themeId":"820bd9599ffb63504ba3f82e9df01528","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its experimental prostate cancer treatment. Under the deal, Vir will receive $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and is eligible for up to an additional $1.37 billion in milestone payments plus royalties on ex-U.S. sales.Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}